Manganese (Mn) and Iron (Fe): Interdependency of Transport and Regulation

Abstract

Biological Importance of Manganese and Iron

The transition metals manganese (Mn) and iron (Fe) are required for proper growth, development, and maintenance of numerous organisms, ranging from bacteria to mammals. Mn, for example, is necessary for the maturation of bones and cartilage (Neilson 2006), increases wound-healing via activation of metal matrix metalloproteinase-2 and −9 (Chebassier et al. 2004), and promotes metabolic activity through its incorporation into pyruvate carboxylase, phosphoenolpyruvate carboxykinase, and arginase (Leach and Harris 1997). While Mn is perhaps best known as a cofactor for the mitochondrially expressed antioxidant protein superoxide dismutase (Miao and St Clair 2009), it is also involved in the production of reactive oxygen species (ROS). Intracellularly, Mn is distributed both in the nuclei and mitochondria (Gunter et al. 2009).

Much like Mn, Fe plays a critical role in normal health and metabolism. Most importantly, however, Fe, incorporated into heme, is required for effective oxygen transport and storage throughout the body (Beard and Dawson 1997). Fe is also an essential cofactor for many of the mitochondrial electron transport chain cytochromes (Mathews et al. 2000). As such, it plays a crucial role in energy production and metabolism. Although accumulation of excess Fe leads to the production of various ROS through Fenton chemistry, Fe, as well as Mn, is an integral structural component of both catalase and peroxidase enzymes, which prevent oxidative stress (Beard and Dawson 1997).

Mn and Fe Transport

Uptake and efflux of both metals must be tightly regulated, as too much or too little of either can result in disease states. Although clinical Mn deficiency is rare, many individuals may not be optimized for Mn levels (Wood 2009). Typically, Mn toxicity results from exposure to greater than 5 lg Mn/m³, which may be found in various industrial settings: welding (Bowler et al. 2006; Park et al. 2007; Sung et al. 2007), metal smelting (Myers et al. 2003b, c), Mn mining (Garcia Avila and Penalver Ballina 1953; Myers et al. 2003a), or battery manufacturing (Bader et al. 1999). Fe overload is also thought to result in or contribute to various disease states, such as hemochromatosis, which affects approximately 1 out of 200 people, primarily from northern European descent (Beaton and Adams 2007). Other disorders, such as thalassemia or chronic liver disease, or environmental factors, such as dietary excess or transfusional overload, may also contribute to high levels of biological Fe (Kohgo et al. 2008). Typically, however, Fe overload is less common than Fe deficiency, which may affect as many as two billion people world wide (WHO 2003) and results in anemic disease states (Jarrah et al. 2007; Skalicky et al. 2006; Toteja et al. 2006; Zhou et al. 2006). As a result, Mn and Fe metabolism, as well as that of numerous other metals, is highly regulated at multiple levels (Jensen et al. 2009; Kaisman-Elbaz et al. 2009; Lee and Beutler 2009; Miyayama et al. 2009; Rondon et al. 2008) to reduce the risk that either too much or too little of the metal poses to normal cellular homeostasis and function. Additionally, the requirements for various metals change during development; thus, many regulatory protein expression patterns vary temporally (Peters et al. 2007; Yang et al. 1997).

Mn and Fe are chemically and structurally similar. For example, both are first-row transition metals with similar atomic masses (Mn: 54.94 amu; Fe: 55.85 amu), radii (Mn: 127 pm; Fe: 125 pm), and electron structure (Mn: [Ar] 3d⁵, 4s²; Fe: [Ar] 3d⁶, 4s²). Their d-shell electrons participate in bonding; they exist in multiple oxidation states; they have similar electronegativity (Mn: 1.55; Fe: 1.83); finally, their initial ionization energies are comparable (Mn: 718 kJ/mol; Fe: 763 kJ/mol). Taken together, it is not surprising that they share many biological protein transporters. On the other hand, Mn ions tend to be more stable in aqueous solution, compared to Fe ions. As a result, Mn is less likely to undergo spontaneous redox cycling, even though both metals have been reported to participate in Fenton chemistry (Gregus 2008). Early reports noted that both metals, in addition to others such as copper and zinc, were transported by the divalent metal transporter-1 (DMT-1; also called NRAMP or Slc11A2; Gunshin et al. 1997), and via the transferrin (Tf)/Tf receptor (TfR) system (Au et al. 2008; Burdo et al. 2003; Mims and Prchal 2005; Rouault and Cooperman 2006). As a result of this overlap in transport, it was hypothesized that mutations in any of these protein transporters might affect the accumulation and homeostasis of both metals. This was borne out in studies involving the Belgrade rat and microcytic mouse model systems, where both metals were disrupted following a mutation in DMT-1 (Chua and Morgan 1997; Fleming et al. 1997).

These data suggested that changes in dietary or environmental levels of either Mn or Fe could lead to dysregulation in tissue levels of these important transition metals. The question of differential Mn and Fe regulation took on new significance in the 1980s following the addition of the gasoline additive methylcyclopentadienyl manganese tricarbonyl in the US and Canada (Abbott 1987; Cooper 1984). As a result, we, and others, undertook a series of studies to determine whether increased Mn levels would affect the availability or concentration of either (1) various transporters or (2) brain Fe distribution and accumulation. Conversely, other studies were designed to determine whether Fe deficiency would lead to greater Mn accumulation, as there would be less blood Fe to compete with Mn for these various transporters. This latter question is important considering that approximately one-third of the world’s population suffers from some degree of Fe deficiency or anemia (de Benoist et al. 2008).

Dietary Manipulation Leads to Brain Metal and Protein Dysregulation

Studies from our lab (Garcia et al. 2006) indicated that developing rat pups receiving milk from dams fed a high Mn diet (100 mg Mn/kg chow; control chow has 10 mg Mn/kg chow and 35 mg Fe/kg chow) had decreased hemoglobin and plasma Fe, but increased plasma Tf and total Fe binding capacity. Additionally, brain Mn, chromium, and zinc accumulation was increased, but brain Fe was lower, compared to controls (Garcia et al. 2006; Guilarte and Chen 2007; Guilarte et al. 2006). Since dysregulation of these metals might have resulted from changes in transport protein levels, Western blot analysis was undertaken to examine expression levels of DMT-1 and TfR. Data indicated an up-regulation of these proteins in multiple brain regions, including cerebellum, cortex, hippocampus, midbrain, and striatum (Garcia et al. 2006).

When pregnant and lactating dams were given either a low-Fe (3.5 mg Fe/kg chow and 10 mg Mn/kg chow) or low-Fe/high-Mn chow (3.5 mg Fe/kg chow and 100 mg Mn/kg chow), various biomarkers in nursing pups and dams resembled those observed in Fe-deficient animals: decreased hemoglobin and plasma Fe, but increased plasma Tf and total Fe binding capacity (Garcia et al. 2007). Similar to high-Mn-treated animals, pups from both treatment groups (low-Fe or low-Fe/high-Mn) showed decreased brain Fe, but increased Mn, copper, chromium, zinc, cobalt, and aluminum. As before, Western blot analysis confirmed increases in DMT-1 and TfR, similar to recent data from young pigs (Hansen et al. 2009). These data suggest that deposition and homeostasis of multiple metals, not just Mn and Fe, were disrupted when these transition metal levels are altered. Interestingly, changes in dietary Mn and Fe also resulted in disruption of various neurotransmitters (Anderson et al. 2007a, b, 2008, 2009). Although it appears that the catecholaminergic neurotransmitters were preferentially affected, γ-aminobutyric acid and glutamate also were regionally affected. These neurochemical changes may help explain why dams fed the low-Fe/high-Mn diet also performed poorly in the Morris water task (Fitsanakis et al. 2009).

Our studies in adult animals receiving subchronic injections of low doses of Mn also reinforce the interdependence of Mn and Fe on their transport. Animals fed normal dietary Fe (35 mg Fe/kg chow), while receiving weekly Mn injections (3 mg Mn/kg body mass), were imaged longitudinally using magnetic resonance (MR) technology. While there was no difference in blood Mn levels at the conclusion of the study, brain Mn was significantly elevated compared to controls (Fitsanakis et al. 2008), particularly in the hippocampus (Finkelstein et al. 2008). There were, however, no statistically significant changes in blood or brain Fe levels. If Mn injections remained the same (3 mg Mn/kg body mass) but dietary Fe concentrations were either increased (300 mg Fe/kg chow) or decreased (3.5 mg Fe/kg chow), brain Mn levels exceeded those of Mn-injected animals alone (Fitsanakis et al. 2008). This was true even for brain regions, such as the cortex and striatum, which did not show any increase in Mn deposition when rats were fed control chow. Additionally, brain Fe actually decreased in the cortex, midbrain, and cerebellum of animals receiving either Fe-deficient or Fe-supplemented food (Fitsanakis et al. 2008). Taken together, these data suggest that brain metal regulation is tightly coupled and that concentration and deposition of multiple metals may be disrupted following excess or deficiency.

Non-Invasive Support for Common Transporters

In general, neither Mn nor Fe exists in high concentrations as a free ion in biological systems due to both the presence of water (forming hydration shells) and the numerous proteins available to incorporate these metals. This is not to say, however, that some fraction is not in a ‘free’ state. Using R₁ and R₂ rate constants from T₁- and T₂-weighted, MR imaging data as a measure of brain Mn and Fe, respectively, mathematical models were derived to estimate the amount of both metals in general bound and unbound states. The best fit was obtained when it was assumed that Fe and Mn are (1) potentially competing for the same binding sites, (2) present in some type of unbound state, or (3) binding to other, non-common, protein sites (Zhang et al. 2009b). Most interesting, however, was the fact that the model predicts that Mn and Fe differentially compete with each other in a regionally specific manner.

For example, the modeling data suggest that most of the Fe in the hippocampus of control animals (24.33 mmol⁻¹/kg tissue) would likely be found bound to sites (other Fe) that may not compete with potential Mn binding sites. Another way of stating this is that 2.20 mmol⁻¹ Fe/kg tissue (bound Fe) is predicted to bind to sites that may also compete with Mn for binding. If one examines data from the cortex, it is likely that more Fe will be found bound to non-Mn competing sites (other Fe) rather than to site that might compete with Mn (bound Fe). This points to a potential for regional specificity related to how Mn and Fe may interact with each other and with various proteins to which they may bind (Table 1; for more extensive information concerning the mathematical equations and the statistical analyses used to validate the model from which data in Table 1 are derived, readers are encouraged to see Zhang et al. 2009b).

While the MR data can suggest information about the apparent binding state of the metals, it cannot provide details about the specific proteins to which the metals are bound. As mentioned above, it is well established that both can bind to DMT-1 and Tf. Other transport proteins, such as those described below, exist as well, which facilitate not only the accumulation, but also the extrusion of Mn and Fe from cells and tissues.

Potential Protein Transporter Interactions

Recent reviews have focused on the ability of DMT-1 (Au et al. 2008; Garrick et al. 2003) and the Tf/TfR system (Macedo and de Sousa 2008; Moos 2002) to transport Mn and Fe in an interdependent manner. Additionally, the relationship between ceruloplasmin and Mn and Fe has been known for many years (Jursa and Smith 2009; Murthy et al. 1981). The most recent study, however, suggested roles for metal transport protein-1 (Wang et al. 2008), ferroportin (Aydemir et al. 2009; Ge et al. 2009; Zhang et al. 2009a), hepcidin (De Domenico et al. 2009; Lee and Beutler 2009), and prion protein (PrP) (Brazier et al. 2008; Choi et al. 2006; Kralovicova et al. 2009) in Fe and Mn transport. Currently, the more complex questions relate to the dependency and interactivity of these proteins on and with one another, and the complex regulation of each by Mn and Fe. As the regulatory roles of hepcidin and PrP to Fe and Mn are likely the least understood, these two proteins, and their interactions with other transporters, will be discussed in further detail.

Hepcidin, Ferroportin, and Transferrin/Transferrin Receptor

Hepcidin is a 25-amino acid hormone that is synthesized in the liver (Rossi 2005). It is known that translation of hepcidin is directly related to Fe levels: increased Fe facilitates hepcidin synthesis, whereas conditions of anemia or Fe deficiency result from decreased hepcidin synthesis. Ultimately, however, it is the interaction of hepcidin with either the Fe-extrusion protein, ferroportin, found, for example, on duodenal enterocytes and macrophages or with DMT-1 (Mena et al. 2006, 2008) that helps maintain Fe homeostasis (De Domenico et al. 2005). Typically, enterocytes and macrophages store or release Fe as plasma levels increase or decrease, respectively. Currently, however, more is known about hepcidin’s interaction with ferroportin and Tf/TfR.

Under the conditions of low plasma Fe, ferroportin increases the release of Fe from these storage cells so that Fe can be transported throughout the body by the Tf/TfR system. Thus, interactions of these three biomolecules are intimately related in the following manner (Fig. 1a): under conditions of high plasma Fe (or high concentrations of the Fe–Tf complex), hepcidin translation is increased; hepcidin binds to ferroportin, causing the membrane-bound ferroportin to be internalized and degraded (De Domenico et al. 2007, 2009); loss of ferroportin leads to decreased Fe extrusion and lower concentrations of plasma Fe available for binging to Tf; and lowered amounts of Fe–Tf complex result in decreased Fe transport throughout the organism. The converse is true when either plasma Fe or Fe–Tf concentrations are low (Fig. 1b). Interestingly, mice with a mutation in the hemochromatosis gene hfe, which is required for normal synthesis of hepcidin, show dysregulation of mitochondrial Fe, Mn, copper, and zinc levels (Jouihan et al. 2008), demonstrating the importance and interrelationship of Fe and Mn homeostasis. Additionally, the hfe gene product, HFE, is thought to compete with Tf for binding of the TfR (Schmidt et al. 2008).

Open in a separate window

Fig. 1

Interrelationship of the biomolecules hepcidin, ferroportin, and Tf/TfR during periods of Fe a excess or b deficiency

Prion Protein

Although PrP is typically most noted for its role in the etiology of transmissible spongiform encephalopathies (Caramelli et al. 2006; Caughey and Chesebro 1997), it is also a known metal-binding protein that is concentrated in synapses (Pocchiari et al. 2009; Singh et al. 2009b). For example, ‘normal’ or cellular PrP (PrP^C) bound to the membrane of cerebellar neurons appears to aid in copper uptake in vitro (Brown 1999) and in vivo (Brown et al. 1997). Additionally, PrP^C has an affinity for nickel, zinc, and Mn (Brown et al. 2000), and has antioxidant properties similar to that of superoxide dismutase (Brown et al. 1997, 1999).

Recent data suggest that PrP^C appears to regulate neuronal Fe uptake and transport (Singh et al. 2009a, b, c). While it had been postulated that the presence of Fe and other redox active compounds catalyzed the conversion of PrP^C to PrP^SC (the pathological variant), it appears more likely now that PrP^C interacts with the Tf/TfR system to transport Fe to ferritin for further storage (Fig. 2). When Singh et al. (2009c) transfected human neuroblastoma cells with PrP^C, cells with increased amounts of PrP^C also demonstrated increased intracellular Fe with a concomitant decrease in Tf and TfR expression. Levels of ferritin were increased, however, suggesting that the cells were appropriately up-regulating the transcription and translation of that Fe storage protein. The authors hypothesize that PrP^C may be involved in intracellular Fe transport through enhancing the binding of Fe to Tf, or facilitating the endocytosis of the Fe–Tf/TfR complex (Singh et al. 2009c), although such speculation was beyond the scope of their studies. Furthermore, loss of PrP^C, either through knocking out the gene or PrP^C conversion to PrP^SC, leads to Fe deficiency (Singh et al. 2009a, b). Considering that PrP^C (1) aids in the transport of Fe, (2) binds Mn and other divalent metals, and (3) may interact directly with Tf, it seems reasonable to consider this novel protein among the various metal transporter candidates more often cited in the literature.

Open in a separate window

Fig. 2

Hypothetical cellular uptake of metals via interactions with the PrP^C and Tf/TfR

Protein–Metal Interactions

Our longitudinal MR studies (Finkelstein et al. 2008; Fitsanakis et al. 2008; Zhang et al. 2009b) involving manipulation of both Mn and Fe suggest that there is either (1) differential competition between Mn and Fe for similar proteins or (2) differential expression of various metal transport proteins. In reality, it is likely a combination of the two. The data (Table 1), however, do provide insight as to predictions for putative concentrations of each metal competitively bound to a transport protein. Furthermore, the data from our model may be useful in suggesting concentrations of Mn or Fe that may be bound to a protein specific for a respective metal, or the metal in its unbound state.

Close examination of the results suggests that for most brain regions, Mn treatment, regardless of the dietary Fe levels, should lead to an increase in brain Mn levels bound to competitive and shared Fe binding sites. Should this hold, the amount of Fe bound to these competitive sites would also significantly decrease. Interestingly, the amount of Fe in other forms (i.e., bound to non-competitive, Fe-specific proteins) also decreases. On the one hand, this could suggest that Mn successfully out-competes Fe for these common Fe-binding sites. These data may also point to the exquisite role Fe plays in regulating proteins that also bind Mn. The latter hypothesis is supported by research related to the importance of the Fe responsive element and Fe regulatory protein pathways (Muckenthaler et al. 2008).

Conclusions

Scientists have identified many proteins involved in the up-take, storage, regulation, and efflux of transition metals, particularly Fe and Mn. In order to understand the primary role of these metals in various organisms, many studies, including those from our lab, have examined biological consequences of altering only Fe or Mn. Questions related to the specific protein(s) involved in the disruption of metal homeostasis, however, were beyond the scope of our noninvasive imaging studies. As we and others have demonstrated, the transport and regulation of these metals appears to be intimately intertwined. It is also likely that manipulation of a single metal will lead to disruption of numerous other metals (Garcia et al. 2006; Liu et al. 2001; Malhotra et al. 1984; Sakai et al. 2004). Thus, knowledge of metal metabolism, regulation, and toxicity will be greatly improved as distribution and accumulation patterns of multiple metals, as well as the binding status of multiple transport proteins, are examined in future studies.

Acknowledgment

Contributor Information

Vanessa A. Fitsanakiss, Department of Biology, King College, Bristol, TN, USA.

Na Zhang, Department of Electrical and Computer Engineering, Clarkson University, Potsdam, NY, USA.

Stephanie Garcia, Department of Physiology and Pharmacology, Wake Forest University, Winston-Salem, NC, USA.

Michael Aschner, Departments of Pediatrics and Pharmacology, Vanderbilt University Medical School, 2215-B Garland Avenue, 11415 Medical Research Building IV, Nashville, TN 37232-0414, USA.

References